Vaxcyte, Inc. (NASDAQ:PCVX) Stake Increased by Paradigm Biocapital Advisors LP

Paradigm Biocapital Advisors LP boosted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 57.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,422,787 shares of the company's stock after acquiring an additional 518,255 shares during the period. Vaxcyte accounts for about 4.1% of Paradigm Biocapital Advisors LP's holdings, making the stock its 8th biggest position. Paradigm Biocapital Advisors LP owned 1.14% of Vaxcyte worth $116,469,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. CIBC Asset Management Inc grew its position in shares of Vaxcyte by 5.5% during the 4th quarter. CIBC Asset Management Inc now owns 3,307 shares of the company's stock valued at $271,000 after purchasing an additional 171 shares in the last quarter. Bridgefront Capital LLC grew its position in shares of Vaxcyte by 4.2% during the 4th quarter. Bridgefront Capital LLC now owns 4,244 shares of the company's stock valued at $347,000 after purchasing an additional 172 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after purchasing an additional 260 shares in the last quarter. Catalyst Funds Management Pty Ltd grew its position in shares of Vaxcyte by 1.7% during the 4th quarter. Catalyst Funds Management Pty Ltd now owns 18,400 shares of the company's stock valued at $1,506,000 after purchasing an additional 300 shares in the last quarter. Finally, Whipplewood Advisors LLC purchased a new position in shares of Vaxcyte during the 4th quarter valued at $28,000. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Stock Performance

Shares of PCVX stock traded up $0.25 during mid-day trading on Monday, reaching $32.10. 669,768 shares of the company's stock traded hands, compared to its average volume of 1,335,848. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $121.06. The firm has a 50 day moving average price of $42.56 and a two-hundred day moving average price of $71.47. The firm has a market capitalization of $4.14 billion, a PE ratio of -6.98 and a beta of 1.27.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same quarter in the previous year, the company earned ($0.85) EPS. As a group, equities analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total value of $586,160.00. Following the sale, the chief operating officer now owns 154,931 shares in the company, valued at $11,351,794.37. The trade was a 4.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.10% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

PCVX has been the subject of a number of recent analyst reports. The Goldman Sachs Group reduced their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Cantor Fitzgerald assumed coverage on shares of Vaxcyte in a research report on Tuesday, April 22nd. They issued an "overweight" rating for the company. Guggenheim reiterated a "buy" rating and issued a $160.00 target price on shares of Vaxcyte in a research report on Wednesday, March 12th. Bank of America cut their target price on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Finally, Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Vaxcyte has an average rating of "Buy" and an average target price of $136.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.